Current issues in chronic graft-versus-host disease.

Chronic graft-versus-host disease (GVHD) is a frequent and potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation. Increased transplantation of older patients and the more frequent use of unrelated donors has led to increased numbers of patients with this painful complication. Recent advances have been made in understanding the pathophysiology of chronic GVHD and in establishing precise criteria for diagnosis and classification of disease manifestations. These advances will hopefully pave the way for improving both the prophylaxis and treatment of chronic GVHD.

[1]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[2]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  T. Braun,et al.  Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. , 2014, Blood.

[4]  H. Greinix,et al.  Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease. , 2013, Blood.

[5]  S. Svegliati,et al.  Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. , 2013, Blood.

[6]  J. Byrd,et al.  Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model , 2013 .

[7]  L. Tian,et al.  Allogeneic HY Antibodies 3 Months Following Sex-Mismatched HCT Predicts Chronic Graft-Versus-Host Disease and Non-Relapse Mortality , 2013 .

[8]  W. Wood,et al.  BCR Hyper-Responsiveness In B Cells From Patients With Chronic Gvhd Is Blocked With The Syk Inhibitor R406 , 2013 .

[9]  J. Ritz,et al.  Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. , 2013, Blood.

[10]  B. Kurland,et al.  Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium , 2013, Bone Marrow Transplantation.

[11]  I. Todorov,et al.  Thymic Damage, Impaired Negative Selection, and Development of Chronic Graft-versus-Host Disease Caused by Donor CD4+ and CD8+ T Cells , 2013, The Journal of Immunology.

[12]  B. Sandmaier,et al.  Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. , 2013, Blood.

[13]  B. Kurland,et al.  Analysis of gastrointestinal and hepatic chronic grant-versus-host disease manifestations on major outcomes , 2013 .

[14]  J. Ritz,et al.  Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease , 2013, Science Translational Medicine.

[15]  B. Sandmaier,et al.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. , 2013, Blood.

[16]  G. Dekan,et al.  CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. , 2013, Blood.

[17]  B. Kurland,et al.  Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  D. Miklos,et al.  H–Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease , 2013, Proceedings of the National Academy of Sciences.

[19]  M. Perales,et al.  Strategies to improve post-transplant immunity , 2013 .

[20]  J. Bourhis,et al.  Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. , 2012, Blood.

[21]  B. Storer,et al.  Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  B. Storer,et al.  Clinical benefit of response in chronic graft-versus-host disease. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  B. Kurland,et al.  Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. , 2012, Blood.

[24]  J. Miguel,et al.  Evaluation of prognostic factors among patients with chronic graft-versus-host disease , 2012, Haematologica.

[25]  B. Narasimhan,et al.  Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. , 2012, Blood.

[26]  A. Böhm,et al.  Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study , 2012, Leukemia.

[27]  B. Kurland,et al.  Validation of measurement scales in ocular graft-versus-host disease. , 2012, Ophthalmology.

[28]  B. Storer,et al.  Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study , 2012, Haematologica.

[29]  J. Ritz,et al.  Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. , 2012, Blood.

[30]  S. Grupp,et al.  Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  J. Ritz,et al.  Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.

[32]  J. Perkins,et al.  The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality , 2011, Haematologica.

[33]  B. Storer,et al.  Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. , 2011, Blood.

[34]  B. Kurland,et al.  Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium , 2011, Haematologica.

[35]  P. Carpenter.  How I conduct a comprehensive chronic graft-versus-host disease assessment. , 2011, Blood.

[36]  Stephanie J. Lee,et al.  Treatment of chronic graft-versus-host disease: Past, present and future , 2011, The Korean journal of hematology.

[37]  D. Porter,et al.  Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2011, Blood.

[38]  J. Klein,et al.  Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. , 2011, Blood.

[39]  H. Einsele,et al.  Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. , 2011, Blood.

[40]  M. Sorror,et al.  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  B. Kurland,et al.  Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. , 2011, Blood.

[42]  J. Serody,et al.  Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. , 2011, Blood.

[43]  R. Storb,et al.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.

[44]  G. Socié.  Chronic GVHD: B cells come of age. , 2011, Blood.

[45]  W. Pickl,et al.  Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia. , 2011, Blood.

[46]  J. Ritz,et al.  Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. , 2011, Blood.

[47]  H. Nakasone,et al.  Association between serum high-molecular-weight adiponectin level and the severity of chronic graft-versus-host disease in allogeneic stem cell transplantation recipients. , 2011, Blood.

[48]  B. Storer,et al.  Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[49]  M. Mohty,et al.  Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  M. Martinka,et al.  Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. , 2010, Blood.

[51]  E. Holler,et al.  Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[52]  R. Porcher,et al.  The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation , 2010, Leukemia.

[53]  M. Robin,et al.  Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections , 2010, Haematologica.

[54]  J. Ritz,et al.  Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. , 2010, The Journal of clinical investigation.

[55]  R. Storb,et al.  Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Storb,et al.  The role of B cells in the pathogenesis of graft-versus-host disease. , 2009, Blood.

[57]  H. Einsele,et al.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. , 2009, The Lancet. Oncology.

[58]  B. Storer,et al.  Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. , 2009, Blood.

[59]  J. Ritz,et al.  Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. , 2009, Blood.

[60]  R. Arceci.  Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease , 2009 .

[61]  K. Schultz.  Chronic Graft versus Host Disease: Interdisciplinary Management: Pathophysiology of Chronic Graft versus Host Disease , 2009 .

[62]  S. Pavletic,et al.  Chronic Graft versus Host Disease: Interdisciplinary Management: Plate section , 2009 .

[63]  N. Chao,et al.  Chronic Graft versus Host Disease: Interdisciplinary Management: Prevention of Chronic Graft versus Host Disease , 2009 .

[64]  S. Pavletic,et al.  Chronic Graft versus Host Disease: Interdisciplinary Management: Diagnosis and Staging , 2009 .

[65]  M. Arora,et al.  Chronic Graft versus Host Disease: Interdisciplinary Management: Incidence and Trends , 2009 .

[66]  S. Lee,et al.  Feasibility of NIH consensus criteria for chronic graft-versus-host disease , 2009, Leukemia.

[67]  A. Hagenbeek,et al.  B-cell involvement in chronic graft-versus-host disease , 2008, Haematologica.

[68]  L. Bouzas,et al.  A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. , 2008, Blood.

[69]  E. Colado,et al.  Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[70]  R. Gress,et al.  Murine models of chronic graft-versus-host disease: insights and unresolved issues. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[71]  Stephanie J. Lee,et al.  Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[72]  G. Cuvelier,et al.  Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. , 2008, Blood.

[73]  E. Cook,et al.  Clinical evaluation of oral chronic graft-versus-host disease. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[74]  J. Ritz,et al.  High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease , 2007, Clinical Cancer Research.

[75]  S. Svegliati,et al.  Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. , 2007, Blood.

[76]  G. Socié,et al.  Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials , 2006, Bone Marrow Transplantation.

[77]  M. Albert,et al.  Assessing the potential role of photopheresis in hematopoietic stem cell transplant , 2006, Bone Marrow Transplantation.

[78]  J. Ritz,et al.  Rituximab for steroid-refractory chronic graft-versus-host disease. , 2006, Blood.

[79]  A. Gabrielli,et al.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. , 2006, The New England journal of medicine.

[80]  P. Bruzzi,et al.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[81]  S. Hirschfeld,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[82]  E. Shpall,et al.  Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. , 2006, Blood.

[83]  L. Gerber,et al.  Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[84]  James Ferrara,et al.  Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[85]  Paul J. Martin,et al.  Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host disease. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[86]  P. Lachenbruch,et al.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[87]  M. Washington,et al.  Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[88]  D. Weisdorf,et al.  Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. , 2005, Blood.

[89]  J. Ritz,et al.  Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. , 2005, Blood.

[90]  Stephanie J. Lee.  New approaches for preventing and treating chronic graft-versus-host disease. , 2005, Blood.

[91]  W. Travis,et al.  Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. , 2005, Blood.

[92]  Catherine J. Wu,et al.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. , 2004, Blood.

[93]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[94]  J. Ritz,et al.  Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation , 2004, The Journal of experimental medicine.

[95]  E. Kansu.  The pathophysiology of chronic graft-versus-host disease , 2004, International journal of hematology.

[96]  M. Flowers,et al.  Chronic graft-versus-host disease. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[97]  J. Ritz,et al.  Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. , 2004, Blood.

[98]  B. Storer,et al.  Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. , 2003, Blood.

[99]  J. Lynch,et al.  Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. , 2003, Blood.

[100]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[101]  B. Storer,et al.  Title : Association between Acute and Chronic Graft -Versus-Host Disease and Bronchiolitis Obliterans Organizing Pneumonia in Recipients of Hematopoietic Stem Cell Transplants Running Head : BOOP and Graft -Versus -Host Disease , 2003 .

[102]  John P Klein,et al.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. , 2002, Blood.

[103]  R. Storb,et al.  Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. , 2002, Blood.

[104]  H. Deeg,et al.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. , 2002, Blood.

[105]  P. Bruzzi,et al.  Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). , 2001, Blood.

[106]  S. Davies,et al.  Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[107]  H. Deeg,et al.  Thalidomide for treatment of patients with chronic graft-versus-host disease. , 2000, Blood.

[108]  J. V. Stone,et al.  Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation , 1999 .

[109]  H. Hönigsmann,et al.  Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. , 1998, Blood.

[110]  B. Bierer,et al.  Treatment of chronic graft-versus-host disease with clofazimine. , 1997, Blood.

[111]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[112]  Jean E. Sanders,et al.  Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. , 1988, Blood.

[113]  S. Spiro.  Diagnosis and staging. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.